These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 31665735)
1. Comparison of Six Different Allergen Extracts for Subcutaneous Specific Immunotherapy in Children: An Open-Labelled, Prospective, Controlled Observational Trial. Kopp MV; König IR; Friedrichs F; Umpfenbach HU; Niggemann B; Millner-Uhlemann M Int Arch Allergy Immunol; 2019; 180(4):284-290. PubMed ID: 31665735 [TBL] [Abstract][Full Text] [Related]
2. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial. Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373 [TBL] [Abstract][Full Text] [Related]
3. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost. Dranitsaris G; Ellis AK J Eval Clin Pract; 2014 Jun; 20(3):225-38. PubMed ID: 24444390 [TBL] [Abstract][Full Text] [Related]
4. Ragweed sublingual tablet immunotherapy: part I - evidence-based clinical efficacy and safety. Creticos PS; Pfaar O Immunotherapy; 2018 Jun; 10(7):605-616. PubMed ID: 29634392 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland. Brüggenjürgen B; Reinhold T J Med Econ; 2018 Apr; 21(4):374-381. PubMed ID: 29271271 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885 [TBL] [Abstract][Full Text] [Related]
7. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937 [TBL] [Abstract][Full Text] [Related]
8. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570 [TBL] [Abstract][Full Text] [Related]
9. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Kim JM; Lin SY; Suarez-Cuervo C; Chelladurai Y; Ramanathan M; Segal JB; Erekosima N Pediatrics; 2013 Jun; 131(6):1155-67. PubMed ID: 23650298 [TBL] [Abstract][Full Text] [Related]
10. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U; Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798 [TBL] [Abstract][Full Text] [Related]